High Noon voluntarily recalls some vodka seltzer drinks mislabeled as energy drinks
What to know about High Noon, Celsius recall
The California-based company announced in a recall announcement Tuesday, which was shared on the U.S. Food and Drug Administration website Wednesday, that some lots of its High Noon Beach Variety packs had been "mislabeled as Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition with a silver top" but were instead "filled with High Noon vodka seltzer alcohol."
"Consumption of the liquid in these cans will result in unintentional alcohol ingestion," the recall warned.
No illnesses or adverse events have been reported in connection with the recall to date, the company said.
The recall impacts two lots: 12-pack High Noon Beach Variety Packs containing 12-fluid-ounce cans, which bear the UPC code 085000040065, and 12-fluid-ounce cans of Celsius Astro Vibe Energy Drink, Sparkling Blue Razz Edition with the UPC code 8 89392 00134 1.
Click here for full lot codes -- which are located on the exterior of the High Noon 12-packs and lasered on the bottom of the Celsius cans -- as well as additional product images.
Poison control centers report spike in calls about kids and energy drinks
High Noon said the recall was initiated after it discovered a "shared packaging supplier mistakenly shipped empty CELSIUS cans to High Noon."
According to the company, the affected products were shipped to distributors in Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia, and Wisconsin, who then shipped those products to retailers in Florida, New York, Ohio, South Carolina, Virginia and Wisconsin between July 21 and 23.
A representative for High Noon shared the company's press release with ABC News and reiterated that the recall was "due to a labeling error from our can supplier."
"We are working with the FDA, retailers and distributors to proactively manage the recall to ensure the safety and well-being of our consumers," the representative said.
Consumers have been advised to dispose of the mislabeled Celsius cans and to "not consume the liquid."
"Even if not purchased in a High Noon Beach Variety pack, consumers should be advised to ensure their CELSIUS ASTRO VIBE Energy Drink, Sparkling Blue Razz Edition does not contain the [recalled] lot codes ... prior to consuming," the company said in its Tuesday announcement.
High Noon Beach Variety packs with lot codes not included in the recall "are safe to consume," the company added.
Consumers can contact High Noon Consumer Relations at consumerrelations@highnoonvodka.com for refund information and details on next steps.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Miami Herald
an hour ago
- Miami Herald
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency - FDA decision expected in 2H'2025 - Access the "What This Means" segment here IRVINE, CA / ACCESS Newswire / August 4, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it participated in a Virtual Investor "What This Means" segment entitled, "enVVeno Medical - Making Veins Work Again - How President Trump's CVI Diagnosis is Raising Awareness." Rob Berman, CEO and Dr. Marc Glickman, CMO of enVVeno Medical discussed the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve® following U.S. Food and Drug Administration (FDA) approval. The Company estimates that there are approximately 2.5 million patients in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025. The "What This Means" segment can be accessed here. About CVI Severe deep venous CVI is a serious and debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments that repair deep venous valve dysfunction, the #1 cause of severe CVI-a disease estimated to cost the U.S. healthcare system in excess of $26 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. INVESTOR CONTACT: Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation
Yahoo
2 hours ago
- Yahoo
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
SAN DIEGO, August 04, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia's digital transformation including technology, data and AI strategy and will serve as a member of the company's Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia. "We are thrilled to welcome Scott to Acadia," said Catherine Owen Adams. "Scott's extensive leadership in digital transformation, AI-driven innovation, and global IT operations across leading biopharmaceutical companies makes him an ideal fit for our organization. His proven ability to scale digital capabilities and drive business value will be instrumental as we continue to grow and evolve." Scott brings over 25 years of experience in the pharmaceutical and biotechnology industries, having held senior leadership roles at Genmab, Biogen, Zoetis, and Pfizer. Most recently, he served as Senior Vice President of Global Information Technology and Digital at Genmab, where he transformed the IT function into a full-scale digital organization, supporting the company's growth from 500 to 2,700 employees and from $750 million to over $3 billion in revenue. Throughout his career, Scott has led enterprise-wide digital and AI initiatives, implemented global ERP and cloud platforms, and driven operational efficiencies through agile methodologies and data analytics. He has also played key roles in major corporate transformations, including IPOs, spin-offs, and M&A integrations. "I am honored to join Acadia at such a pivotal time," said Scott Cenci. "The opportunity to contribute to a company that is deeply committed to investing in data, technology, and AI to accelerate innovation and improved patient care is incredibly exciting. I look forward to partnering with the team to advance Acadia's digital capabilities and support its mission to bring new therapies to patients." Scott holds an MBA in Management Information Systems from Seton Hall University and a BS in Computer Science and a minor in Mathematics from The College of New Jersey. He has served as an advisor to professional organizations and is an active member of the Osage Venture Partners Technology Advisory Board. Additionally, Scott has served as a speaker on topics such as Generative AI and digital transformation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. View source version on Contacts Investor Contact: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
3 hours ago
- Business Wire
Family Health Services of Darke County and AndHealth Celebrate Ribbon Cutting and Launch of Retail + Specialty Pharmacy at Expanded Greenville Location
GREENVILLE, Ohio--(BUSINESS WIRE)--Family Health Services of Darke County and AndHealth will celebrate the opening of Family Health Services' retail and specialty pharmacy on Thursday, August 7 th at 4:00 PM. The ribbon cutting will take place at Family Health Services' newly expanded Greenville facility, located at 5735 Meeker Road, and will be followed by an open house from 5:00 – 8:00 PM featuring light refreshments, family-friendly activities, and tours of the renovated space. "With this expansion, we're not just adding services, we're closing care gaps and removing barriers to health for our neighbors.' This milestone marks a major step forward in Family Health Services' mission of Building Healthy Lives Together. This expansion adds 44,000 square feet of clinical space, modernizes the patient experience, and introduces expanded pharmacy services, including the launch of Darke County's only specialty pharmacy. These enhancements will significantly improve access for patients managing chronic and complex conditions, particularly those impacted by long-standing pharmacy shortages in rural Ohio. Family Health Services' specialty pharmacy services are powered by a partnership with AndHealth, a Columbus-based healthcare company that helps CHCs radically improve access and outcomes to specialty care. Ohioans can now fill their prescriptions directly through Family Health Services' pharmacy, where affordable medications are available to all patients under Family Health Service's sliding fee scale. 'There is an immense value in having specialty care and pharmacy services directly within our community,' said Jared Polick, Executive Director and CEO of Family Health Services. 'Residents of Darke County will now be able to receive care close to home and have the personal support of local clinical pharmacists and specialists. With this expansion, we're not just adding services, we're closing care gaps and removing barriers to health for our neighbors.' The updated Greenville facility now offers integrated medical, behavioral health, dental, rheumatology, dermatology, neurology, and pharmacy services under one roof – creating a true whole-person care environment that prioritizes convenience, coordination, and affordability. Addressing Ohio's Pharmacy Deserts and Improving Medication Access According to new data 1 released by the Ohio Board of Pharmacy, pharmacy closures have accelerated, and the state has lost hundreds of pharmacies over the past several years, leaving Ohioans with less than 2,000 retail pharmacies. Nearly 2 million Ohioans live in 'pharmacy deserts', or areas that lack convenient access to a pharmacy. 2 These access deserts disproportionately impact individuals in socially vulnerable communities, who face additional barriers to access and care, making the role of pharmacies located at CHCs even more central to improving community health in Ohio. AndHealth partners with Community Health Centers (CHCs) like Family Health Services to expand access to care by addressing pharmacy and care deserts. 'Ensuring our patients have access to affordable medications can only be accomplished when we reverse the trend of pharmacy consolidation and closure,' said Brenda Reitz, Family Health Services' Pharmacy Director. 'This pharmacy expansion allows us to support the community in new ways and ensures our neighbors needs can be met right here in Darke County.' Family Health Services' ribbon cutting will take place at its 5935 Meeker Rd location in Greenville at 4:00 P.M. on August 7 th with an open house to follow from 5:00 – 8:00 PM. The event is open to all, and guests are encouraged to RSVP by contacting Kalie Riffle at kriffle@ About Family Health Services Family Health Services is a Federally Qualified Health Center (FQHC) dedicated to building healthier lives through integrated, affordable care. With locations across Darke County, FHS provides comprehensive services – including medical, dental, behavioral health, specialty care, and pharmacy – to patients of all ages, regardless of insurance status or ability to pay. To learn more, visit About AndHealth AndHealth helps Community Health Centers (CHCs) radically improve access and outcomes for patients in specialty care and specialty pharmacy, while becoming an even larger and more clinically integrated part of our healthcare system. This Whole-Person Community Care Model provides everything CHCs need to deliver in-house specialty care and specialty pharmacy, built for the unique needs of our medically underserved populations. The model provides CHCs with more patients, more clinical capabilities, alignment with health systems, and sustainable reimbursement and funding that restores the integrity of the patient's medical home and their critical reimbursement model—both having shifted away from CHCs through external specialty referrals and contract pharmacies. In restoring this integrity, CHCs can tear down barriers to care and stretch scarce federal resources to reach more patients with comprehensive services that weren't possible before and that are desperately needed by patients. Headquartered in Columbus, Ohio, AndHealth is led by former CoverMyMeds co-founder and CEO Matt Scantland and the team that built Ohio's first healthcare technology unicorn, who have dedicated their lives to transformative innovation that improves access for patients. AndHealth is supported by key investors including the American Medical Association's innovation subsidiary, Francisco Partners, and the state of Ohio's economic development organization. To learn more, visit